Bikanta
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Bikanta - overview
Established
2013
Location
Newark, NJ, US
Primary Industry
Medical Devices & Equipment
About
Bikanta is a biotechnology company that develops advanced therapies for various medical conditions, focusing on innovative biomolecules and effective drug delivery systems to enhance patient outcomes. Founded in 2013 in Newark, US, Bikanta specializes in innovative biotechnological solutions. The company participated in a Seed funding round in June 2014, raising USD 0. 12 mn led by Y Combinator.
No pivots or changes in operations have been noted since its inception, and there are no references to subsidiaries or parent companies. Bikanta specializes in advanced biotechnological solutions, with a focus on the development and commercialization of innovative therapies. Their core offerings include proprietary biomolecules and drug delivery systems aimed at treating conditions such as cancer, regenerative medicine, and immune modulation. Serving a diverse clientele including research institutions and pharmaceutical companies, Bikanta continues to expand its product line to meet unmet medical needs across North America, Europe, and parts of Asia.
Bikanta generates revenue primarily through strategic partnerships and B2B transactions with healthcare institutions and pharmaceutical companies. Their model involves direct negotiations to establish tailored agreements, including licensing and collaborative research. Flagship products are priced at a premium due to their advanced capabilities, ensuring competitiveness while supporting ongoing innovations. The company emphasizes long-term partnerships with a dedicated client base to capitalize on the demand for biotechnological solutions.
Bikanta's strategy for future growth includes the design and launch of new products aimed at addressing specific medical conditions, although specific release dates are not provided. The company plans to expand into additional markets, targeting regions in Asia and Europe by 2025. Recent funding from the Seed round in June 2014 will be utilized to support these initiatives and further develop their product lines, enhancing their market presence.
Current Investors
Y Combinator
Primary Industry
Medical Devices & Equipment
Sub Industries
Diagnostic Equipment
Website
www.bikanta.com
Verticals
Nanotechnology
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.